Evidence map›Paper›PMID 26993372›Full record

Trial reportDrug and alcohol dependence2016

Ibudilast attenuates subjective effects of methamphetamine in a placebo-controlled inpatient study.

Matthew J Worley, Aimee-Noelle Swanson, Keith G Heinzerling, Daniel J O Roche, Steve Shoptaw

Erratum issued Registry-linked trialOpen access · greenAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Drug and alcohol dependence, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT04706624 (Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics), which is not on this map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
6.2field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04706624 nacompletednot on this mapstarted 2021, after this paper: background citation

Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics

TypeinterventionalSponsorHanoi Medical UniversityRan2021 to 2025Enrolled667ConditionsMethamphetamine Abuse, Opioid-use Disorder, HIV SeropositivityArmsContingency management (12 weeks), Contingency management (6 weeks), SMS reminders, Matrix only, Matrix + Contingency management
3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 55 citations in OpenAlex.

  1. Trial
  2. Randomized, Placebo-Controlled Trial of Targeting Neuroinflammation with Ibudilast to Treat Methamphetamine Use Disorder.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2020
    Trial
  3. Trial
  4. Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2017
    Trial
  5. Trial
  6. The neuroimmune-glutamate hypothesis of addiction.Neuroscience and biobehavioral reviews · 2026
    Review
  7. Review
  8. Review
  9. Substance Addiction Rehabilitation Drugs.Pharmaceuticals (Basel, Switzerland) · 2024
    Review
  10. Article
  11. Article
  12. Article
  13. Review
  14. Role of Microglia in Psychostimulant Addiction.Current neuropharmacology · 2023
    Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Toll-Like Receptor 4: A Novel Target to Tackle Drug Addiction?Handbook of experimental pharmacology · 2022
    Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Matthew J WorleyDepartment of Family Medicine, University of California, Los Angeles, 10880 Wilshire Blvd., Suite 1800, Los Angeles, CA 90024, United States. Electronic address: mworley@ucsd.edu.
Aimee-Noelle Swanson
Keith G HeinzerlingDepartment of Family Medicine, University of California, Los Angeles, 10880 Wilshire Blvd., Suite 1800, Los Angeles, CA 90024, United States.
Daniel J O RocheDepartment of Psychology, University of California, Los Angeles, Franz Hall, Los Angeles, CA 90095, United States.
Steve ShoptawDepartment of Family Medicine, University of California, Los Angeles, 10880 Wilshire Blvd., Suite 1800, Los Angeles, CA 90024, United States.
University of California, Los Angeles · US

Funding

Randomized Trial of Ibudilast for Methamphetamine DependenceR01DA035054 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HEINZERLING, KEITH GREGORY · 2012 to 2017
$3.3M
Varenicline for Methamphetamine DependenceR01DA030577 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHOPTAW, STEVEN J · 2011 to 2013
$1.8M
UCLA Training Program on Addiction Medicine in Primary CareT32DA026400 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHOPTAW, STEVEN J · 2009 to 2013
$1.3M
Phase I Safety Interaction Trial of Ibudilast with MethamphetamineR01DA029804 · NIDA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI SHOPTAW, STEVEN J · 2010 to 2012
$1.1M
NIDA NIH HHS 5R01DA029804NIDA NIH HHS 5R01 DA030577NIDA NIH HHS 5T32 DA026400NIDA NIH HHS L30 DA038321NIDA NIH HHS R01 DA029804NIDA NIH HHS R01 DA030577NIDA NIH HHS R01 DA035054NIDA NIH HHS T32 DA026400
6 · The paper itself

Abstract

backgroundDespite numerous clinical trials no efficacious medications for methamphetamine (MA) have been identified. Neuroinflammation, which has a role in MA-related reward and neurodegeneration, is a novel MA pharmacotherapy target. Ibudilast inhibits activation of microglia and pro-inflammatory cytokines and has reduced MA self-administration in preclinical research. This study examined whether ibudilast would reduce subjective effects of MA in humans.

methodsAdult, non-treatment seeking, MA-dependent volunteers (N=11) received oral placebo, moderate ibudilast (40 mg), and high-dose ibudilast (100mg) via twice-daily dosing for 7 days each in an inpatient setting. Following infusions of saline, MA 15 mg, and MA 30 mg participants rated 12 subjective drug effects on a visual analog scale (VAS).

resultsAs demonstrated by statistically-significant ibudilast × MA condition interactions (p<.05), ibudilast reduced several MA-related subjective effects including High, Effect (i.e., any drug effect), Good, Stimulated and Like. The ibudilast-related reductions were most pronounced in the MA 30 mg infusions, with ibudilast 100mg significantly reducing Effect (97.5% CI [-12.54, -2.27]), High (97.5% CI [-12.01, -1.65]), and Good (97.5% CI [-11.20, -0.21]), compared to placebo.

conclusionsIbudilast appeared to reduce reward-related subjective effects of MA in this early-stage study, possibly due to altering the processes of neuroinflammation involved in MA reward. Given this novel mechanism of action and the absence of an efficacious medication for MA dependence, ibudilast warrants further study to evaluate its clinical efficacy.

Indexed as

RewardAdultAmphetamine-Related DisordersCross-Over StudiesDouble-Blind MethodFemaleHumansIndolizinesInpatientsMaleMethamphetamineMiddle AgedPyrazolesPyridinesSelf AdministrationVasodilator AgentsibudilastIndolizinesMethamphetaminePyrazolesPyridinesVasodilator AgentsIbudilastMethamphetamineNeuroinflammationPharmacotherapySubjective reward

Identifiers

PMID26993372
PMCPMC5349508
OpenAlexW2289861197

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.